Use of aerosolized antibiotics in patients with cystic fibrosis.
Campbell
P W
PW
Saiman
L
L
D000336:Aerosols; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001424:Bacterial Infections / Q000150:complications / Q000517:prevention & control*; D003550:Cystic Fibrosis / Q000150:complications*; D016903:Drug Monitoring; D004352:Drug Resistance, Microbial; D006801:Humans; D018579:Patient Selection; D011552:Pseudomonas Infections / Q000150:complications / Q000517:prevention & control; D012141:Respiratory Tract Infections / Q000150:complications / Q000517:prevention & control*; D014031:Tobramycin / Q000008:administration & dosage
D000336:Aerosols; D000900:Anti-Bacterial Agents; D014031:Tobramycin